PepsRadar
⌕ Search✧ Ask
PRODUCT KNOWLEDGE · BioLongevity Labs
A three-component listing: GHK-Cu, BPC-157, and a TB-500-labeled component. These notes apply to this supplier's 70 mg version.
DECLARED COMPOSITION
70 mg totalSeller describes a lyophilized vial. The composition below is attributed to this listing; it is not an independent measurement.
| Listed ingredient | Declared amount | Identity & research context |
|---|---|---|
| GHK-Cu | 50 mg | Copper complex, distinct from free GHK. GHK-Cu research context → |
| BPC-157 | 10 mg | Named ingredient; batch identity not independently verified. BPC-157 research context → |
| TB-500 label · identity discrepancy | 10 mg | Description refers to an actin-binding region, but the specifications give a 43-residue sequence. Both pages are identity context; neither verifies the batch. TB-500 research context →Thymosin beta-4 research context → |
Composition source: Supplier composition and product description ↗ (affiliate link). A shared blend name can refer to different ingredients, ratios, or identities at another supplier.
Identity discrepancy: the description refers to the actin-binding region of thymosin beta-4, while the sequence table lists 43 residues and a full-length molecular weight. The exact TB-500-labeled component needs clarification and batch-specific verification.
Based on Supplier composition and product description ↗ (affiliate link); batch composition has not been independently verified.
These are selected studies of individual ingredients or related identities. They did not validate the seller's finished blend. Open the linked profile for the population, design, results, and limitations.
Animal / laboratory study · 2013
Effects of topical copper tripeptide complex on wound healing in an irradiated rat model.
Read profile evidence → · Original publication ↗Rat tendon-cell study · 2014
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.
Read profile evidence → · Original publication ↗Related-peptide mechanistic review · 2010
Biological activities of thymosin beta4 defined by active sites in short peptide sequences.
Read profile evidence → · Original publication ↗Human randomized trial · 2015
Did ophthalmic treatment meet the primary dry-eye endpoints?
Read profile evidence → · Original publication ↗Different ingredients or plausible mechanisms do not establish synergy. A research-use designation is not a finding of clinical safety or efficacy.
Price and availability are dated listing snapshots. Shipping, taxes, options, and later changes are excluded.
Supplier composition and product description ↗ (affiliate link)
Direct link · No affiliate commission active. Listing inclusion does not verify the product or endorse the supplier.
A product description or general purity claim does not verify every ingredient or ratio in a purchased lot. Match the lot identifier, analytes, methods, and quantitative results to the specific material; a certificate does not establish a clinical outcome.
Browse product knowledge → · Browse supplier catalog →
Educational product reference. No dosing, mixing, or administration instructions are provided. Medical and full-formulation evidence review remain pending.